• Purity

  >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its ability to inhibit IL-22-induced IL-10 secretion by COLO 205 human colorectal adenocarcinoma cells. The ED    ₅₀ for this effect is 1-4 μg/mL in the presence of 0.5 ng/mL of Recombinant Mouse IL-22 (Catalog # ).

• Source

  Mouse myeloma cell line, NS0-derived

  Mouse IL-22BP (Thr19-Pro230) Accession # Q08AV1	IEGRMDP	Mouse IgG2A (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Thr19

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  51.8 kDa (monomer)

• SDS-PAGE

  60-70 kDa, reducing conditions

Background: IL-22BP

Interleukin 22 binding protein (IL-22BP), also known as CRF2-10, CRF2-X, and IL-22 RA2, is a 35-45 kDa secreted glycoprotein in the type II cytokine receptor family (CRF). IL-22 signals through a receptor complex consisting of IL-22 R and IL-10 R beta. IL-10 R beta is also a component of the receptor complexes for IL-10, IL-26, IL-28, and IL-29 (1, 2). IL-22BP blocks the interaction of IL-22 with IL-22 R, preventing IL-22 induced production of reactive oxygen species, IL-6, IL-10, and TNF-a (3-8).   In vivo, it regulates the proinflammatory effects of IL-22 (  e.g. neutrophil infiltration) but not of IL-10 (7). Mouse IL-22BP can neutralize the bioactivity of both mouse and human IL-22 (6). IL-22BP is produced by dendritic cells (DE), epithelial cells, activated B cells, and activated monocytes (3, 6, 9, 10). It is constitutively expressed by DC but is down-regulated during local inflammation and in response to tissue damage (11-13). IL-22BP is critical for limiting IL-22 induced epithelial cell proliferation during wound healing, and its deficiency can enable uncontrolled proliferation and enhance tumor development (12). Mature mouse IL-22BP consists of two tandem Fibronectin type-III domains and shares 85% and 68% amino acid sequence identity with rat IL-22BP and the short isoform of human IL-22BP, respectively (6, 14).

• References:

1. Lim, C. and R. Savan (2014) Cytokine Growth Factor Rev. 25:257.

2. Mizoguchi, A. (2012) Inflamm. Bowel Dis. 18:1777.

3. Xu, W. et al. (2001) Proc. Natl. Acad. Sci. USA 98:9511.

4. Kotenko, S.V. et al. (2001) J. Immunol. 166:7096.

5. Li, J. et al. (2004) Int. Immunopharmacol. 4:693.

6. Wei, C.-C. et al. (2003) Genes Immun. 4:204.

7. Weber, G.F. et al. (2007) Infect. Immun. 75:1690.

8. Whittington, H.A. et al. (2004) Am. J. Respir. Cell Mol. Biol. 31:220.

9. Lecart, S. et al. (2002) Int. Immunol. 14:1351.

10. Nagalakshmi, M.L. et al. (2004) Int. Immunopharmacol. 4:577.

11. Wolk, K. et al. (2007) J. Immunol. 178:5973.

12. Huber, S. et al. (2012) Nature 491:259.

13. Martin, J.C.J. et al. (2014) Mucosal Immunol. 7:101.

14. Weiss, B. et al. (2004) Genes Immun. 5:330.

• Long Name:

  Interleukin 22 Binding Protein

• Entrez Gene IDs:

  116379 (Human); 237310 (Mouse)

• Alternate Names:

  class II cytokine receptor; CRF2-10; CRF2-S1IL22BP; CRF2-X; Cytokine receptor class-II member 10; Cytokine receptor family 2 member 10; Cytokine receptor family type 2, soluble 1; IL-22 RA2; IL-22 receptor subunit alpha-2; IL22BP; IL-22BP; IL-22BPCRF2X; IL22RA2; IL-22RA2; IL-22R-alpha-2; interleukin 22 receptor, alpha 2; interleukin 22-binding protein; interleukin-22 receptor subunit alpha-2; Interleukin-22-binding protein; MGC150509; MGC150510; zcytoR16